

IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Jae Keol RHEE, et al.

Appln. No.: 10/596,412

Confirmation No.: Unknown



Docket No: Q95351

Group Art Unit: Unknown

Examiner: Unknown

Filed: June 13, 2006

For: NOVEL OXAZOLIDINONE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. S. Bae et al., "High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates", Journal of Chromatography B, (2003), pp. 397-403.
2. EP Patent Application No. 0 352 781 A2, published January 31, 1990.
3. WO 03/022824 A1, published March 20, 2003 to Astrazeneca UK Limited.
4. WO 01/94342 A1, published December 13, 2001 to Dong A Pharm. Co., Ltd.
5. WO 93/23384 A1, published November 25, 1993 to The UPJOHN COMPANY.
6. WO 95/14684 A1, published June 1, 1995 to The UPJOHN COMPANY.

Jae-Keol RHEE, et al.  
U.S. Appln. No.: 10/596,412  
INFORMATION DISCLOSURE STATEMENT

7. WO 95/07271 A1, published March 16, 1995 to The UPJOHN COMPANY.

8. WO 93/09103 A1, published May 13, 1993 to The UPJOHN COMPANY.


One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
Sunhee Lee  
Registration No. 53,892

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**


CUSTOMER NUMBER

Date: August 31, 2006

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet

1

of 1

*Complete if Known*

Application Number	10/596,412
Confirmation Number	Unknown
Filing Date	June 13, 2006
First Named Inventor	Jae Keol RHEE
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q95351

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		EP	0 352 781	A2	01/31/1990	E.I. DuPont De Nemours and Company	
		WO	03/022824	A1	03/20/2003	Astrazeneca UK Limited	
		WO	01/94342	A1	12/13/2001	Dong A Pharm. Co., Ltd.	
		WO	93/23384	A1	11/25/1993	The UPJOHN COMPANY	
		WO	95/14684	A1	06/01/1995	The UPJOHN COMPANY	
		WO	95/07271	A1	03/16/1995	The UPJOHN COMPANY	
		WO	93/09103	A1	05/13/1993	The UPJOHN COMPANY	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		S. Bae et al., "High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates", Journal of Chromatography B, (2003), pp. 397-403.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.